The total comprehensive income grew 3 per cent at Rs 113 crore

Ajanta Pharma posted in Q4 and 12 months FY 2017 consolidated audited results, approved by its Board of Directors. In Q4 FY 2017, the company’s income from operations grew 11 per cent at Rs 477 crore against Rs 431 crore. It posted EBITDA growth of 23 per cent at Rs 174 crore against Rs 142 crore and EBITDA was at 36 per cent of revenue. Profit after tax (PAT) grew five per cent at Rs 114 crore against Rs 109 crore and PAT was at 24 per cent of revenue. The total comprehensive income grew 3 per cent at Rs 113 crore against Rs 110 crore.

In the year ended FY 2017, the company’s income from operations grew 14 per cent at Rs 2,002 crore against Rs 1,749 crore. It posted EBITDA growth of 19 per cent at Rs 701 crore against Rs 587 crore and EBITDA was at 35 per cent of revenue. PAT grew 22 per cent at Rs 507 crore against Rs 416 crore, which was at 25 per cent of revenue. The total comprehensive income grew 20 per cent at Rs 504 crore against Rs 421 crore.